NEW YORK (GenomeWeb) – Rubicon Genomics today announced that it has extended a clinical supply agreement providing its TransPlex whole-genome RNA amplification technology to Agendia for use in its MammaPrint 70-Gene breast cancer recurrence assay.

In early 2012, Agendia first inked the deal to use Rubicon's technology to analyze formalin-fixed, paraffin-embedded (FFPE) breast cancer samples on its Symphony suite of diagnostics, which includes MammaPrint.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.